- Home
- News
- us virgislands
- immune development
Refine by
Immune Development Articles & Analysis
86 news found
BioZyme’s mission is to provide an undeniable positive impact on the health and wellness of the animals it serves. Therefore, BioZyme and its staff continually research and create products to help animals and maximize efficiencies for producers. With our mission and commitment to care that comes full circle in mind, we are excited to introduce VitaFerm® Sure Start Gel. VitaFerm Sure ...
CD BioSciences, a US-based biotechnology company focusing on the development of imaging technologies, is excited to announce the launch of its new Immune System Tissue Microarrays for the scientific community to study the complex interactions of the immune system in various tissues. These innovative products offer researchers a powerful tool to ...
Despite progress, an effective animal model that mimics human immune response during HIV/TB co-infection has been lacking, hindering treatment and vaccine development. Bohorguez et al. (2024) developed a humanized NSG-SGM3 mouse model to advance HIV/TB co-infection studies. These mice are transplanted with human CD34+ stem cells, enabling the ...
This premier event, held May 3-7, 2024, at McCormick Place in Chicago, IL, brought together renowned researchers from around the world to share the latest developments in immunology. As an exhibitor at booth #512, Creative BioMart highlighted its extensive range of products designed to support immunology research. The company's portfolio includes immune ...
Some species of Fusarium can also cause a host of infections. People with healthy immune systems may develop infections of the nails or cornea. There have even been past investigations by the Centers for Disease Control and Prevention of outbreaks of Fusarium keratitis that were associated with contaminated eye products. People with weakened ...
(NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicines is one of NASDAQ's top gainers today and the stock is trending on Yahoo Finance, currently trading at $3.8955, up $1.6955 or 77.0682%. ...
When people breathe in the spores, they are at risk of developing histoplasmosis. After the spores enter the lungs, a person’s body temperature allows the spores to transform into yeast. ...
In addition, the role of mTOR in the development and regulation of the immune system is rapidly emerging. Insights into this paradigm are expected to link the regulation of pathways to the restoration of immune homeostasis for the treatment of a wide range of diseases, including infectious diseases, autoimmune disorders, allograft rejection and ...
When people breathe in the spores, they are at risk of developing histoplasmosis. After the spores enter the lungs, a person’s body temperature allows the spores to transform into yeast. ...
Biolojic Design also has partnerships with Nektar Therapeutics for the development of antibodies against autoimmune diseases and Eli Lilly for the development of antibodies that fight diabetes. ...
Melbourne, Australia, 09 January 2023 – Cartherics Pty Ltd (“Cartherics”), a biotechnology company developing immune cell therapies for the treatment of cancer, announced today that it has been granted Chinese patent ZL 201680069543.6, entitled “Genetically modified cells and uses thereof”. ...
An important element of the AFRIMS mission is to support the development of vaccines against viruses that are endemic in the Southeast Asia region. ...
For Ardigen, it is the opportune time to work even more effectively on new therapeutics in clinical development to support and guide healthcare needs in the development of medicine. ...
ByArdigen
Secreted proteins are a proven class of biologics with tremendous therapeutic potential, as they regulate tissue repair and regeneration, organ development, and immune response to disease. However, despite the remarkable impact of FDA-approved biologics based on secreted proteins such as insulin, human growth hormone, and erythropoietin, this class of biologics ...
She brings with her extensive knowledge and experience in the field of Immuno-Oncology and drug discovery, which is strategic for Ardigen’s development. Agnieszka Blum, MD, PhD will continue her mission as the General Director of the Immunology Business Unit at Ardigen, where she focuses on developing AI platforms to solve therapy ...
ByArdigen
IO-108 is being studied as a monotherapy and in combination with select anti-PD-1 antibodies in multiple expansion cohorts of solid tumors Clinical supply agreement with Regeneron accelerates Immune-Onc’s solid tumor clinical development program Immune-Onc Therapeutics, Inc. ...
The company aims to translate unique scientific insights in myeloid cell biology and immune inhibitory receptors to discover and develop first-in-class biotherapeutics that inhibit immune suppression in the tumor microenvironment. ...
Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a private, clinical-stage cancer immunotherapy company developing novel biotherapeutics targeting myeloid checkpoints, today announced it has entered into a clinical trial collaboration and supply agreement with to evaluate Immune-Onc’s first-in-class myeloid ...
Schmitt will significantly help refine our development in a strategic direction for the Immunology Business Unit”. ...
ByArdigen
Immune-Onc is leading the way in China in the development and potential commercialization of myeloid checkpoint inhibitors, such as IO-108. ...